Controversy in the Treatment of ADHF: Limited Role for Nesiritide
The use of nesiritide for acute decompensated heart failure (ADHF) has been clouded with controversy since its approval in 2001. Extensive marketing and many review articles have established this drug as a safe and superior product to current standards. However, its safety has been called into question by the results of a meta-analysis, and its superiority of important outcomes (length of stay, mortality, decreased readmission rate) has never been proved by a randomized trial against agents with similar vasodilator properties (e.g., nitroglycerin). A review of the available literature on nesiritide in the areas of mortality, renal effects, retrospective studies, use in off-label indications, length of stay, and mortality is presented and illustrates why its use should be limited or even eliminated. After review of this article, the reader should be able to answer the question—if nesiritide had never been approved for use in patients with ADHF, would we have missed it?—with a negative reply.

As to diseases, make a habit of two things—to help, or at least, to do no harm.
Hippocrates

Nesiritide (Natrecor; Scios Inc., Sunnyvale, CA) was approved in the United States in 2001 for the treatment of acute decompensated heart failure (ADHF). Although deemed safe and efficacious, results from a recent meta-analysis have questioned the agent's safety.